SAB Biotherapeutics
SAB Biotherapeutics, Inc.
SAB Biotherapeutics is a clinical-stage biopharmaceutical company that develops fully-human, multi-targeted immunoglobulins (IgGs) for treating immune and autoimmune disorders. The company utilizes its proprietary DiversitAb™ platform, which involves genetically engineered cattle (Tc Bovine), to produce large quantities of targeted human antibodies without requiring human donors. This innovative approach is aimed at addressing a variety of unmet medical needs.
Products & Team
SAB-142
SAB-142 is the company's lead product candidate, a fully-human anti-thymocyte globulin developed as a disease-modifying immunotherapy for Type 1 Diabetes (T1D). It is designed to specifically target and deplete T-cells that are responsible for destroying insulin-producing beta cells in the pancreas.
It addresses the root cause of Type 1 Diabetes by targeting the autoimmune response, with the goal of delaying the onset and slowing the progression of the disease in at-risk individuals.
SAB addresses the lack of effective, disease-modifying treatments for certain autoimmune disorders like T1D. For infectious diseases, it tackles the challenges posed by highly mutating viruses and the limitations of therapies reliant on human donor plasma, offering a method for rapid, scalable production of targeted antibodies.